BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 37519144)

  • 21. Core-needle biopsy is more useful than repeat fine-needle aspiration in thyroid nodules read as nondiagnostic or atypia of undetermined significance by the Bethesda system for reporting thyroid cytopathology.
    Na DG; Kim JH; Sung JY; Baek JH; Jung KC; Lee H; Yoo H
    Thyroid; 2012 May; 22(5):468-75. PubMed ID: 22304417
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Implications of a suspicious afirma test result in thyroid fine-needle aspiration cytology: an institutional experience.
    Lastra RR; Pramick MR; Crammer CJ; LiVolsi VA; Baloch ZW
    Cancer Cytopathol; 2014 Oct; 122(10):737-44. PubMed ID: 25123499
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The impact of repeat fine-needle aspiration in thyroid nodules categorized as atypia of undetermined significance or follicular lesion of undetermined significance: A single center experience.
    Marin F; Murillo R; Diego C; Jodar E; Acevedo A
    Diagn Cytopathol; 2021 Mar; 49(3):412-417. PubMed ID: 33252841
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Malignancy risk and characteristics of thyroid nodules with two consecutive results of atypia of undetermined significance or follicular lesion of undetermined significance on cytology.
    Park VY; Kim EK; Kwak JY; Yoon JH; Moon HJ
    Eur Radiol; 2015 Sep; 25(9):2601-7. PubMed ID: 25740802
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Diagnostic Performance of Ultrasound Patterns by K-TIRADS and 2015 ATA Guidelines in Risk Stratification of Thyroid Nodules and Follicular Lesions of Undetermined Significance.
    Hong HS; Lee JY
    AJR Am J Roentgenol; 2019 Aug; 213(2):444-450. PubMed ID: 31039023
    [No Abstract]   [Full Text] [Related]  

  • 26. Noninvasive Follicular Variant of Papillary Thyroid Carcinoma and the Afirma Gene-Expression Classifier.
    Wong KS; Angell TE; Strickland KC; Alexander EK; Cibas ES; Krane JF; Barletta JA
    Thyroid; 2016 Jul; 26(7):911-5. PubMed ID: 27219469
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Real-World Performance of the Afirma Genomic Sequencing Classifier (GSC)-A Meta-analysis.
    Nasr CE; Andrioli M; Endo M; Harrell RM; Livhits MJ; Osakwe I; Polavarapu P; Siperstein A; Wei S; Zheng X; Jiang R; Hao Y; Huang JIN; Klopper JP; Kloos RT; Kennedy G; Angell TE
    J Clin Endocrinol Metab; 2023 May; 108(6):1526-1532. PubMed ID: 36470585
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Risk Stratification of Thyroid Nodules With Atypia of Undetermined Significance/Follicular Lesion of Undetermined Significance (AUS/FLUS) Cytology Using Ultrasonography Patterns Defined by the 2015 ATA Guidelines.
    Lee JH; Han K; Kim EK; Moon HJ; Yoon JH; Park VY; Kwak JY
    Ann Otol Rhinol Laryngol; 2017 Sep; 126(9):625-633. PubMed ID: 28719972
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Fine-needle aspiration cytology repetition in thyroid nodules with non-diagnostic findings or atypia of undetermined significance/follicular lesions of undetermined significance: Does time matters?
    Benido Silva V; Borges Duarte D; Teresa Pereira M; Couto de Carvalho A; Freitas C
    Ann Endocrinol (Paris); 2022 Aug; 83(4):232-236. PubMed ID: 35489413
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Repeat Fine Needle Aspiration Cytology Refines the Selection of Thyroid Nodules for Afirma Gene Expression Classifier Testing.
    Nishino M; Mateo R; Kilim H; Feldman A; Elliott A; Shen C; Hasselgren PO; Wang H; Hartzband P; Hennessey JV
    Thyroid; 2021 Aug; 31(8):1253-1263. PubMed ID: 33813868
    [No Abstract]   [Full Text] [Related]  

  • 31. ThyroSeq v3 for Bethesda III and IV: An institutional experience.
    Desai D; Lepe M; Baloch ZW; Mandel SJ
    Cancer Cytopathol; 2021 Feb; 129(2):164-170. PubMed ID: 33030808
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The impact of atypia/follicular lesion of undetermined significance and repeat fine-needle aspiration: 5 years before and after implementation of the Bethesda System.
    Sullivan PS; Hirschowitz SL; Fung PC; Apple SK
    Cancer Cytopathol; 2014 Dec; 122(12):866-72. PubMed ID: 25078420
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Thyroid nodule molecular profiling: The clinical utility of Afirma Xpression Atlas for nodules with Afirma Genomic Sequencing Classifier-suspicious results.
    Babazadeh NT; Sinclair TJ; Krishnamurthy V; Jin J; Heiden KB; Shin J; Berber E; Siperstein A
    Surgery; 2022 Jan; 171(1):155-159. PubMed ID: 34924179
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparison of Afirma Gene Expression Classifier with Gene Sequencing Classifier in indeterminate thyroid nodules: A single-institutional experience.
    Geng Y; Aguilar-Jakthong JS; Moatamed NA
    Cytopathology; 2021 Mar; 32(2):187-191. PubMed ID: 33010060
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The Effect Modification of Ultrasound Risk Classification on Molecular Testing in Predicting the Risk of Malignancy in Cytologically Indeterminate Thyroid Nodules.
    Hu TX; Nguyen DT; Patel M; Beckett K; Douek M; Masamed R; Rhyu J; Kim J; Tseng CH; Yeh MW; Livhits MJ
    Thyroid; 2022 Aug; 32(8):905-916. PubMed ID: 35611970
    [No Abstract]   [Full Text] [Related]  

  • 36. Thyroid nodules classified as atypia or follicular lesions of undetermined significance deserve further research: Analysis of 305 surgically confirmed nodules.
    Turkyilmaz S; Ulusahin M; Celebi B; Cekic AB; Mungan S; Kucuktulu U; Tasdelen A; Guner A; Cinel A
    Cytopathology; 2017 Oct; 28(5):391-399. PubMed ID: 28714532
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Single Institution Experience with Afirma and Thyroseq Testing in Indeterminate Thyroid Nodules.
    Gortakowski M; Feghali K; Osakwe I
    Thyroid; 2021 Sep; 31(9):1376-1382. PubMed ID: 33764195
    [No Abstract]   [Full Text] [Related]  

  • 38. Risk factors associated with malignancy and with triage to surgery in thyroid nodules classified as Bethesda category III (AUS/FLUS).
    Kuru B; Atmaca A; Tarim IA; Kefeli M; Topgul K; Yoruker S; Elmali M; Danaci M
    Eur J Surg Oncol; 2016 Jan; 42(1):87-93. PubMed ID: 26527545
    [TBL] [Abstract][Full Text] [Related]  

  • 39. UTILITY OF AFIRMA GENE EXPRESSION CLASSIFIER FOR EVALUATION OF INDETERMINATE THYROID NODULES AND CORRELATION WITH ULTRASOUND RISK ASSESSMENT: SINGLE INSTITUTIONAL EXPERIENCE.
    Sultan R; Levy S; Sulanc E; Honasoge M; Rao SD
    Endocr Pract; 2020 May; 26(5):543-551. PubMed ID: 31968199
    [No Abstract]   [Full Text] [Related]  

  • 40. Repeat fine-needle aspiration can be performed at 6 months or more after initial atypia of undetermined significance or follicular lesion of undetermined significance results for thyroid nodules 10 mm or larger.
    Koh J; Kim EK; Kwak JY; Yoon JH; Moon HJ
    Eur Radiol; 2016 Dec; 26(12):4442-4448. PubMed ID: 26965502
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.